Evaluating the efficacy of eicosapentanoic acid on modified Rankin scale and inflammatory biomarkers in patients with ischemic stroke.

Evaluating the Efficacy of Eicosapentaenoic Acid compared to placebo on Modified Rankin Scale and Inflammatory Biomarkers in Patients with Ischemic Stroke: A Randomized Controlled Trial.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170608034390N15

Enrollment

Registered

2024-07-31

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: Patients take an oral softgel containing 1000 mg of eicosapentaenoic acid in two divided doses, morning and evening, on a full stomach for 3 months. Intervention 2:

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 18 years Ischemic stroke Hospitalized in neurology ward

Exclusion criteria

Exclusion criteria: Patients that are under treatment with Alteplase Patients with the history of allergy to fish liver oil and its derivatives. Patients with platelet level Count 20).

Design outcomes

Primary

Measure	Time frame
Modified Rankin Scale (mRS) in patients. Timepoint: At the time of hospitalization, before discharge, and 3th months. Method of measurement: Clinical Scale.	—

Secondary

Measure	Time frame
National Institute of Health Stroke Scale in patients. Timepoint: At the time of hospitalization, before discharge, and at third month. Method of measurement: Clinical Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Esmaily

Shahid Beheshti University of Medical Sciences

Esmaily_hadi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jul 3, 2026